English, Article edition: Cost Effectiveness of Desirudin Compared with a Low Molecular Weight Heparin in the Prevention of Deep Vein Thrombosis after Total Hip Replacement Surgery Lars-Ake Levin; David Bergqvist

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93359
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Desirudin Compared with a Low Molecular Weight Heparin in the Prevention of Deep Vein Thrombosis after Total Hip Replacement Surgery
Author
  • Lars-Ake Levin
  • David Bergqvist
Physical Description
  • article
Notes
  • Objectives: This prospective pharmacoeconomic study analyses and discusses the cost effectiveness (expressed as cost per life-year gained) of desirudin in comparison with a low molecular weight heparin (LMWH), enoxaparin, as prophylaxis against deep vein thrombosis (DVT) in total hip replacement. Methods: The cost effectiveness was analysed on the basis of results from a clinical trial that compared the recombinant hirudin, desirudin, with the LMWH, enoxaparin. The trial results regarding the incidence of DVT are included together with epidemiological data in a decision tree, simulating long term cost effectiveness of patients undergoing elective hip replacement. The model includes Markov processes simulating patients up to the age of 85 years, including the costs of DVT-related long term complications. Results: The average total thrombosis-related cost per patient under prophylactic therapy with enoxaparin is 7022 Swedish kronor (SEK) compared with SEK7497 when using desirudin (1998 values). The total costs with desirudin are 7% higher. Prophylaxis with desirudin in those patients undergoing elective hip replacement surgery adds, on average, 7 days of life per patient when compared with treatment using enoxaparin. This is equivalent to 1.91 additional years of life per 100 patients treated. The incremental cost-effectiveness ratio of prophylaxis with desirudin in patients undergoing elective hip replacement surgery is SEK24 864 per life-year gained in comparison with enoxaparin. Conclusion: The present study demonstrates that prophylactic therapy with desirudin is a cost-effective approach for the prevention of DVT in patients undergoing total hip replacement.
  • Antithrombotics, Cost effectiveness, Deep vein thrombosis, Desirudin, Enoxaparin sodium, Low molecular weight heparins, Pharmacoeconomics
  • RePEc:wkh:phecon:v:19:y:2001:i:5:p:589-597
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment